




# **Bridging Clinical Gaps in Indolent and Aggressive B-Cell Lymphomas:** The Investigators Demonstrate How Novel Mechanisms Will Impact Your Practice Tomorrow

**LIVE WEBCAST**

**FRIDAY, DECEMBER 9, 2022**

11:00 AM – 2:00 PM CST

*For more information, visit us at...*

**gotoper.com**



**STAY CONNECTED!** Follow us @GoToPER and share your thoughts and photos by using #gotoper.

# AGENDA

|          |                                                                                                      |
|----------|------------------------------------------------------------------------------------------------------|
| 11:00 AM | Welcome and Introductions                                                                            |
| 11:05 AM | Addressing Unmet Needs and Current Challenges in B-Cell Lymphoma                                     |
| 11:15 AM | Increasing Therapeutic Options for Patients With Mantle Cell Lymphoma: Evidence From Clinical Trials |
| 11:50 AM | Applying Novel Therapies in the Therapeutic Continuum of Follicular Lymphoma                         |
| 12:25 PM | Emerging Therapeutic Options for the Management of Marginal Zone Lymphoma                            |
| 1:00 PM  | New Horizons for Treatment of DLBCL: Key Clinical Data                                               |
| 1:35 PM  | Optimizing Delivery of Treatment in NHL: Key Takeaways                                               |
| 1:50 PM  | Post-Test and Audience Q&A                                                                           |

| Upcoming PER® Conferences                                                                                                        |                      | 2022           |
|----------------------------------------------------------------------------------------------------------------------------------|----------------------|----------------|
| Inaugural International Congress Pediatric Oncology                                                                              |                      | December 16    |
|                                                                                                                                  |                      | 2023           |
| <i>The 1st Annual Hawaii Lung: A Multidisciplinary Case-Based Conference™</i>                                                    | Honolulu, HI         | January 21     |
| <i>20th Annual Winter Lung Conference®</i>                                                                                       | Hollywood, FL        | February 3-5   |
| <i>19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®</i>                                         | Dallas, TX           | February 4     |
| <i>27th Annual International Congress on Hematologic Malignancies®</i>                                                           | Miami Beach, FL      | February 23-26 |
| <i>40th Annual Miami Breast Cancer Conference®</i>                                                                               | Miami Beach, FL      | March 2-5      |
| <i>NYGU™ 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies</i>                        | New York, NY         | March 10-11    |
| <i>8th Annual School of Gastrointestinal Oncology®</i>                                                                           | Orlando, FL          | May 6          |
| <i>7th Annual International Congress on Oncology &amp; Pathology™: Towards Harmonization of Pathology and Oncology Standards</i> |                      | May 6          |
| <i>14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies</i>                                  |                      | May 13         |
| <i>22nd Annual International Congress on the Future of Breast Cancer® East</i>                                                   | New York, NY         | July 15-16     |
| <i>24th Annual International Lung Cancer Congress®</i>                                                                           | Huntington Beach, CA | July 27-29     |
| <i>22nd Annual International Congress on the Future of Breast Cancer® West</i>                                                   | San Diego, CA        | July 28-29     |
| <i>20th Annual Meeting of the International Society of Gastrointestinal Oncology®</i>                                            | Tempe, AZ            | October 13-14  |
| <i>21st Annual School of Breast Oncology®</i>                                                                                    | Atlanta, GA          | November 2-4   |
| <i>41st Annual CFS®: Innovative Cancer Therapy for Tomorrow®</i>                                                                 | New York, NY         | November 8-10  |
| <i>18th Annual New York Lung Cancers Symposium®</i>                                                                              | New York, NY         | November 11    |



Virtual Conference



In-Person + Virtual Conference



In-Person Conference

## Faculty, Staff, and Planners' Disclosures

The staff of Physicians' Education Resource®, LLC have no relevant financial relationships with ineligible companies.

### Program Chair



**Andre H. Goy, MD**

Physician-in-Chief  
Hackensack Meridian *Health* Oncology Care Transformation Service  
Chairman & Chief Physician Officer  
John Theurer Cancer Center  
Lydia Pfund Chair for Lymphoma  
Academic Chairman, Oncology - Hackensack Meridian School of Medicine  
Professor of Medicine - Georgetown University  
Hackensack, NJ

**Disclosures:** *Grant/Research Support:* PI (Reserach to insitution) -Acerta, AstraZenca, Bristol Meyers, Celgene, Genentech, Genentech-Hoffman La Roche, Hoffman La Roche,Infinity, Janseen, Karyopharm, Kite pharma, MorphoSys, Pharmacyclics, Seattle Genetics. Verastem; *Stock/Shareholder:* COTA, Alloplex, Resilience, Genomic Testing Cooperative; *Other:* Advisory/ Board-Kite, Gilead, Pharmacyclics, Elsevier's PracticeUpdate Oncology, Janseen Biotech; Board of Directors- COTA, Resilience, Genomic Testing Cooperative; Consulting Faculty- Roswell Park, Michael J Hennessey Associates, INC, Phsysicians Education Resource, LLC; Scientific Advisory Board- Alloplex, BMS, Vincerx; Steering Committee- Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc.

### Faculty



**Lorenzo Falchi, MD**

Assistant Attending Physician  
Lymphoma Service  
Department of Medicine  
Memorial Sloan Kettering Cancer Center  
New York, NY

**Disclosures:** *Grant/Research Support:* Genentech/Roche, Genmab; *Consultant:* Genentech/Roche, Genmab, Abbvie, ADC Therapeutics, AstraZeneca; *Other Support:* CME Presentation: Projects in Knowledge (Kaplan); Journal Editor: Taylor Francis.

**Lori A. Leslie, MD**

Director, Indolent Lymphoma and Chronic Lymphocytic Leukemia Research Programs  
John Theurer Cancer Center  
Associate Professor  
Hackensack Meridian School of Medicine  
Hackensack University Medical Center  
Hackensack, NJ

**Disclosures:** *Consultant:* Beigene, SeaGen, Abbvie, Epizyme, Janssen, Pharmacyclics, Kite/Gilead, AstraZeneca, Merck, Celgene, TG therapeutics, Lilly; *Speakers' Bureau:* SeaGen, Eli Lilly, KitePharma, BeiGene, Pharmacyclics/Janssen, AstraZeneca, Epizyme, TG therapeutics, Karyopharm.

**Michael L. Wang, MD**

Puddin Clarke Endowed Professor  
Department of Lymphoma and Myeloma  
University of Texas MD Anderson Cancer Center  
Houston, TX

**Disclosures:** *Grant/Research Support:* Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Celgene, Genentech, Innocare, Janssen, Juno, Kite Pharma, Lilly, Loxo Oncology, Molecular Templates, Oncternal, Pharmacyclics, VelosBio; *Consultant:* AstraZeneca, Bayer Healthcare, BeiGene, CSTone, DTRM Biopharma (Cayman) Limited, Epizyme, Genentech, InnoCare, Janssen, Juno, Kite Pharma, Loxo Oncology, Miltenyi Biomedicine, GmbH, Oncternal, Pharmacyclics, VelosBio; *Speakers' Bureau:* Acerta Pharma, Anticancer Association, AstraZeneca, BeiGene, CAHON, Chinese Medical Association, Clinical Care Options, Dava Oncology, Epizyme, Hebei Cancer Prevention Federation, Imedex, Janssen, Kite Pharma, Miltenyi Biomedicine GmbH, Moffit Cancer Center, Mumbai Hematology Group, Newbridge Pharma.

PER<sup>®</sup> mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

## Off-Label Disclosure and Disclaimer

This accredited CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing medical and/or nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER<sup>®</sup> or any of the companies that provided commercial support for this activity.

# ACTIVITY OVERVIEW

## Target Audience

These activities are intended for medical oncologists, hematologists, and other oncology healthcare professionals interested in the latest advances in the treatment of patients with non-Hodgkin lymphoma. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with non-Hodgkin lymphoma are also invited to attend.

## Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

- Describe diagnostic and prognostic biomarkers that guide treatment planning in indolent and aggressive B-cell malignancies
- Integrate safety and efficacy data for emerging treatment options, including chemotherapy-free regimens, to clinical scenarios in patients with B-cell NHL
- Identify strategies to mitigate, monitor, and manage adverse events associated with therapeutic regimens used in the treatment of patients with B-cell NHL
- Assess recently reported and ongoing clinical trials of novel agents and therapeutic combinations for patients with indolent and aggressive B-cell malignancies

## How to Claim Credit

The evaluation and request for credit will be available at the end of the webcast and will remain available until January 23, 2023, only. To request credit, please visit

<https://gotoper.com/ash22bcell-eval>

## e-Syllabus

Final Final slides will be uploaded to the e-Syllabus on the PER website by 8:00pm Eastern Time on Monday, December 12, 2022.

To access these materials, please visit the website: <http://gotoper.com/ash22bcell-esyl>

Thank you for attending  
**Bridging Clinical Gaps in Indolent and Aggressive B-Cell Lymphomas:  
The Investigators Demonstrate How Novel Mechanisms Will Impact Your  
Practice Tomorrow.**

To register for upcoming oncology accredited CE conferences or view our online  
accredited CE activities, please visit [www.gotoper.com](http://www.gotoper.com).

We appreciate your participation and look forward to seeing you at future  
PER<sup>®</sup> accredited CE activities.

### Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 3.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### Acknowledgement of Education Grant Support


This activity is supported by educational grants from Genmab, Kite Pharma, Inc., and Kyowa Kirin, Inc.

# Did you miss one of our sessions?


Check out the On-Demand Video Updates  
from the Annual Hematology Meeting

## —*Rapid Archive from*→ **NEW ORLEANS**


Archive will be available 24 hours after the live program ends.



**Optimized use of MRD in  
Hematologic Malignancies**




**State-of-the-Art CMV Care**




**Emerging Treatments for  
Anemia in CKD**



**Holistic Approaches in  
Sickle Cell Disease Treatment**




**Diagnosis and Treatment of  
Hemolytic Anemias**




**Optimized Treatments for  
ALL in Adolescents and Adults**




**Multidisciplinary Management  
of BPDCN**




**Maximizing Clinical Practice  
for Hodgkin Lymphoma**



**State-of-the-Art Care for  
MF and PV**




**Exploring Gene Therapy in  
Hemophilia B**



**Diagnosing Uncommon  
Hematologic Disorders**



**Novel Therapies to Prevent  
and Treat GvHD**



**Novel Treatments for Indolent  
and Aggressive B-Cell Lymphomas**



**Treating Transfusion-Related  
Iron Overload**



Scan the QR code below  
or visit [gotoper.com/ASH22](https://gotoper.com/ASH22)  
to view the symposia archive.

 **PER**<sup>®</sup>  
Physicians'  
Education  
Resource, LLC  
[gotoper.com](https://gotoper.com)